Episode: FDA Approval Insights: Dabrafenib Plus Trametinib for BRAF V600E–Mutated Unresectable or Metastatic Solid Tumors
Description: Dr Subbiah highlights the significance of the FDA approval of dabrafenib and trametinib in adult and pediatric patients at least 6 years of age with BRAF V600E–mutant metastatic or unresectable solid tumors and contextualizes the pivotal data for rare tumor types.
Click any word to see translations, usage examples & similar words. Then learn them using saved words.
Text not synced with the audio? See here for why certain podcasts won't sync.
